Meet the PI
J. William Harbour, M.D.
Dr. Harbour is Professor and Chair of the Department of Ophthalmology at UT Southwestern Medical Center. He specializes in ocular oncology.
Dr. Harbour earned his medical degree at Johns Hopkins University and completed a residency in ophthalmology at the Wills Eye Hospital of Thomas Jefferson University. He received advanced training through a fellowship in vitreoretinal diseases and surgery at the Bascom Palmer Eye Institute of the University of Miami, a fellowship in ocular oncology at the University of California, San Francisco, and research training in molecular oncology at Washington University in St. Louis.
Certified by the American Board of Ophthalmology, he joined the UT Southwestern faculty in 2021.
Previously, Dr. Harbour held the Dr. Mark J. Daily, M.D., Endowed Chair at the Bascom Palmer Eye Institute, where he also served as Director of Ocular Oncology and Vice Chair for Translational Research. He also served as Associate Director for Basic Science at the Sylvester Comprehensive Cancer Center of the University of Miami.
Dr. Harbour’s clinical interests focus on ocular tumors such as uveal melanoma, retinoblastoma, and lymphoma. He has trained many residents and fellows and pioneered new surgical methods in fine needle biopsy, laser treatment, and brachytherapy of ocular tumors. He also has been awarded patents for innovations in genetic prognostic testing for uveal melanoma.
His research interests include the use of genetic and genomic technologies to better understand, diagnose, and treat eye cancers. His team discovered three of the most important genomic drivers of metastasis in uveal melanoma, as well as key genomic events in retinoblastoma. His contributions to the field have been recognized by the Association for Research in Vision and Ophthalmology’s Cogan Award and the Macula Society’s Paul Henkind and Rosenthal Awards, among many others.
Dr. Harbour has delivered more than 300 invited scientific lectures and published more than 200 peer-reviewed scientific articles and book chapters.
He is an Associate Editor for Melanoma Research and has served on the editorial boards of Archives of Ophthalmology, Translational Vision Science & Technology, Melanoma Management, Expert Review of Ophthalmology, and Faculty of 1000.
Dr. Harbour is a member of numerous professional organizations, including the Association of American Physicians, American Academy of Ophthalmology, American Association for Cancer Research, and American Association of Ophthalmic Oncologists and Pathologists, and he is the founder of the Collaborative Ocular Oncology Group.
Contact Us
- Harbour Lab
- The Harbour Lab is located in the Simmons Comprehensive Cancer Center on the 5th floor of the NB building on North Campus.
- 6000 Harry Hines Blvd. Dallas, TX 75390 NB5.230 (5th floor, room 230)
Lab Members
Mahsa Sorouri, Ph.D. (Lab Manager)
Jie Han, M.S. (Research Scientist)
Mithalesh Singh, Ph.D. (Postdoc)
Mechanisms of Tumor Progression in Eye Cancer
Dr. J. William Harbour’s research focuses on the use of genetic and genomic technology, cell biology, and genetically modified experimental animal models to elucidate mechanisms of tumor progression and metastasis in major forms of lethal eye cancers, including uveal melanoma and retinoblastoma.
Uveal Melanoma
Over the past two decades, the Harbour Laboratory has made great strides in understanding uveal melanoma, the most common primary cancer of the eye. The lab found that uveal melanomas can be divided into two basic forms, based on gene expression profile, mutation status, and chromosomal alterations. Class 1 uveal melanomas have low metastatic risk, whereas class 2 uveal melanomas have high metastatic risk. Based on this discovery, the lab developed a clinical prognostic test based on a 15-gene signature that has been prospectively validated in multiple studies and is currently the standard of care for precision medicine in this cancer type. Further, the lab discovered that mutational inactivation of the tumor suppressor BAP1 accounts for the class 2 uveal melanoma tumor type, as well as a novel BAP1 familial cancer syndrome, which is transmitted in an autosomal dominant fashion and can include uveal and cutaneous melanoma, mesothelioma, renal cell carcinoma, meningioma, and other cancer types.
Recently, the lab discovered that the cancer-testis antigen PRAME can be aberrantly expressed in uveal melanoma, representing an independent prognostic factor in both class 1 and class 2 uveal melanomas. Further work in the lab has disclosed a functional role for PRAME in chromosomal instability, aneuploidy, and tumor progression.
Retinoblastoma
The Harbour Laboratory has established tumor samples and cell lines from a large number of primary human retinoblastoma samples and has undertaken an unprecedented scope and depth of genomic analysis that has disclosed a new understanding of retinoblastoma progression. The lab discovered ESRRG as one of the key drivers of retinoblastoma progression. This estrogen-related orphan receptor plays an essential role in retinal development, hypoxic adaptation, and retinoblastoma progression.
Research Directions
Major research directions in the lab include:
- Elucidate how BAP1 mutations and aberrant PRAME expression drive uveal melanoma progression, with a focus on how these genomic aberrations alter the tumor immune microenvironment.
- Elucidate how aberrant ESRRG expression and other recurrent genomic aberrations in retinoblastoma drive tumor progression, metastasis, and poor prognosis, with a focus on altered oxygen metabolism.
- Determine how to therapeutically disrupt key drivers of tumor progression in uveal melanoma and retinoblastoma.
Harbour JW, Kurtenbach S, Sanchez M, Kuznetsoff J, Rodriguez D, Weich N, Dollar J, Cruz A, Kurtenbach S, Field M, Decatur C, Sorouri M, Lai F, Shiekhattar R, Pelaez D, Correa Z, Verdun R,
2023 Apr
Res Sq
Kaler CJ, Dollar JJ, Cruz AM, Kuznetsoff JN, Sanchez MI, Decatur CL, Licht JD, Smalley KSM, Correa ZM, Kurtenbach S, Harbour JW,
2022 Jul
Cancers (Basel)
15
14
Field MG, Kuznetsoff JN, Zhang MG, Dollar JJ, Durante MA, Sayegh Y, Decatur CL, Kurtenbach S, Pelaez D, Harbour JW,
2022 Aug
Sci Adv
33
8
eabm8466
2022 08
Lancet Glob Health
8
10
e1128-e1140
Multiregional genetic evolution of metastatic uveal melanoma.
Rodriguez DA, Yang J, Durante MA, Shoushtari AN, Moschos SJ, Wrzeszczynski KO, Harbour JW, Carvajal RD, 2021 Aug NPJ Genom Med 1 6 70Impact of Genetic Ancestry on Prognostic Biomarkers in Uveal Melanoma.
Rodriguez DA, Sanchez MI, Decatur CL, Correa ZM, Martin ER, Harbour JW, 2020 Oct Cancers (Basel) 11 12Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer.
Carbone M, Harbour JW, Brugarolas J, Bononi A, Pagano I, Dey A, Krausz T, Pass HI, Yang H, Gaudino G, 2020 08 Cancer Discov 8 10 1103-1120Single-cell analysis reveals new evolutionary complexity in uveal melanoma.
Durante MA, Rodriguez DA, Kurtenbach S, Kuznetsov JN, Sanchez MI, Decatur CL, Snyder H, Feun LG, Livingstone AS, Harbour JW, 2020 01 Nat Commun 1 11 496
Kuznetsov JN, Aguero TH, Owens DA, Kurtenbach S, Field MG, Durante MA, Rodriguez DA, King ML, Harbour JW,
2019 09
Sci Adv
9
5
eaax1738
Field MG, Kuznetsov JN, Bussies PL, Cai LZ, Alawa KA, Decatur CL, Kurtenbach S, Harbour JW,
2019 09
Clin Cancer Res
18
25
5663-5673
Genomic evolution of uveal melanoma arising in ocular melanocytosis.
Durante MA, Field MG, Sanchez MI, Covington KR, Decatur CL, Dubovy SR, Harbour JW, 2019 08 Cold Spring Harb Mol Case Stud 4 5Punctuated evolution of canonical genomic aberrations in uveal melanoma.
Field MG, Durante MA, Anbunathan H, Cai LZ, Decatur CL, Bowcock AM, Kurtenbach S, Harbour JW, 2018 01 Nat Commun 1 9 116PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma.
Field MG, Decatur CL, Kurtenbach S, Gezgin G, van der Velden PA, Jager MJ, Kozak KN, Harbour JW, 2016 Mar Clin Cancer Res 5 22 1234-42Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma.
Harbour JW, Roberson ED, Anbunathan H, Onken MD, Worley LA, Bowcock AM, 2013 Feb Nat Genet 2 45 133-5
Onken MD, Worley LA, Char DH, Augsburger JJ, Correa ZM, Nudleman E, Aaberg TM, Altaweel MM, Bardenstein DS, Finger PT, Gallie BL, Harocopos GJ, Hovland PG, McGowan HD, Milman T, Mruthyunjaya P, Simpson ER, Smith ME, Wilson DJ, Wirostko WJ, Harbour JW,
2012 Aug
Ophthalmology
8
119
1596-603
Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, Council ML, Matatall KA, Helms C, Bowcock AM,
2010 Dec
Science
6009
330
1410-3
Carvajal RD, Sacco JJ, Jager MJ, Eschelman DJ, Olofsson Bagge R, Harbour JW, Chieng ND, Patel SP, Joshua AM, Piperno-Neumann S,
2023 Feb
Nat Rev Clin Oncol
2
20
99-115
Peters V, Gurayah A, Jin W, Kwon D, Zhao W, Patel NV, Markoe A, Correa Z, Studenski MT, Harbour JW, Samuels SE,
2022 Sep
Brachytherapy
Marquez MA, Fortun J, Iyer P, Harbour JW, Haddock LJ,
2022 Sep
Am J Ophthalmol Case Rep
27
101614
Sanati-Mehrizy A, Ghosh T, Peterson E, Starke RM, Harbour JW, Corrales-Medina FF,
2022 May
J Pediatr Hematol Oncol
4
44
181-185
HDAC11 activity contributes to MEK inhibitor escape in uveal melanoma.
Sriramareddy SN, Faião-Flores F, Emmons MF, Saha B, Chellappan S, Wyatt C, Smalley I, Licht JD, Durante MA, Harbour JW, Smalley KSM, 2022 Mar Cancer Gene Ther
Goel N, Yadegarynia S, Kwon D, Kesmodel SB, Harbour JW, Kobetz E, Merchant N, Rodriguez DA,
2022 Jun
Ann Surg
Pyruvate dehydrogenase inactivation causes glycolytic phenotype in BAP1 mutant uveal melanoma.
Han A, Chua V, Baqai U, Purwin TJ, Bechtel N, Hunter E, Tiago M, Seifert E, Speicher DW, Schug ZT, Harbour JW, Aplin AE, 2022 Jan Oncogene
Baqai U, Purwin TJ, Bechtel N, Chua V, Han A, Hartsough EJ, Kuznetsoff JN, Harbour JW, Aplin AE,
2022 Apr
Mol Cancer Res
Khine KT, Clark WM, Harbour JW,
2021 Oct
JAMA Ophthalmol
Structural Protein Analysis of Driver Gene Mutations in Conjunctival Melanoma.
Djulbegovic MB, Uversky VN, Harbour JW, Galor A, Karp CL, 2021 Oct Genes (Basel) 10 12Functional impact of titin (TTN) mutations in ocular surface squamous neoplasia.
Djulbegovic MB, Uversky VN, Karp CL, Harbour JW, 2021 Nov Int J Biol Macromol
Han A, Purwin TJ, Bechtel N, Liao C, Chua V, Seifert E, Sato T, Schug ZT, Speicher DW, Harbour JW, Aplin AE,
2021 Mar
Oncogene
9
40
1753
Comprehensive assessment of the effect of eye plaque tilt on tumor dosimetry.
Studenski MT, Markoe A, Samuels SE, Correa ZM, Bossart E, Harbour JW, 2021 Jun BrachytherapyIris metastasis from breast cancer successfully treated with Abemaciclib and Letrozole.
Goduni L, Ashkenazy N, Hansen E, Soyano-Muller A, Correa ZM, Harbour JW, 2021 Jun Retin Cases Brief RepUphyloplot2: visualizing phylogenetic trees from single-cell RNA-seq data.
Kurtenbach S, Cruz AM, Rodriguez DA, Durante MA, Harbour JW, 2021 Jun BMC Genomics 1 22 419Therapeutic Escape in Gaq-mutant Uveal Melanoma: It's a FAK.
Harbour JW, 2021 Jun Clin Cancer Res 11 27 2967-2969Secondary Glaucoma Associated with Intraocular Metastatic Cutaneous Melanoma.
Greenfield JA, Rowlands M, Harbour JW, 2021 Jul Ophthalmol Glaucoma
Wagley S, Belin PJ, Dollar JJ, Harbour JW, Maltry AC, Mruthyunjaya P, Schefler AC, Tang PH,
2021 Jul
Am J Ophthalmol
Ashkenazy N, Walter SD, Harbour JW,
2021 Jul
JAMA Ophthalmol
7
139
802-803
Garoon RB, Medina CA, Scelfo C, Harbour JW,
2021 Jan
Retin Cases Brief Rep
1
15
68-70
Alsina KM, Sholl LM, Covington KR, Arnal SM, Durante MA, Decatur CL, Stone JF, Oelschlager KM, Harbour JW, Monzon FA, Cook RW, Borman S,
2021 Dec
Ocul Oncol Pathol
6
7
428-436
The AMP-dependent kinase pathway is upregulated in BAP1 mutant uveal melanoma.
Chua V, Han A, Bechtel N, Purwin TJ, Hunter E, Liao C, Harbour JW, Aplin AE, 2021 Aug Pigment Cell Melanoma ResKinetic Characterization of ASXL1/2-Mediated Allosteric Regulation of the BAP1 Deubiquitinase.
Peng H, Cassel J, McCracken DS, Prokop JW, Sementino E, Cheung M, Collop PR, Polo A, Joshi S, Mandell JP, Ayyanathan K, Hinds D, Malkowicz SB, Harbour JW, Bowcock AM, Salvino J, Kennedy EJ, Testa JR, Rauscher FJ, 2021 07 Mol Cancer Res 7 19 1099-1112Multimodal Imaging in the Diagnosis of Exophytic Juxtapapillary Retinal Capillary Hemangioblastoma.
Russell JF, Villegas VM, Schwartz SG, Weng CY, Davis JL, Flynn HW, Harbour JW, 2021 05 Am J Ophthalmol 225 128-136PieParty: visualizing cells from scRNA-seq data as pie charts.
Kurtenbach S, Dollar JJ, Cruz AM, Durante MA, Decatur CL, Harbour JW, 2021 05 Life Sci Alliance 5 4
Kuznetsoff JN, Owens DA, Lopez A, Rodriguez DA, Chee NT, Kurtenbach S, Bilbao D, Roberts ER, Volmar CH, Wahlestedt C, Brothers SP, Harbour JW,
2021 02
Mol Cancer Res
2
19
215-222
Armitage AM, Kundra MA, Ghiam N, Atwal PS, Morel D, Hruska KS, Torene R, Harbour JW, Forghani I,
2021 01
Am J Med Genet A
1
185
208-212
Influence of tumor shape and location in eye plaque brachytherapy dosimetry.
Studenski MT, Patel NV, Markoe A, Harbour JW, Samuels SE, 2020 Mar - Apr Brachytherapy 2 19 249-254Bilateral uveitis associated with nivolumab therapy for metastatic non-small cell lung cancer.
Dermarkarian CR, Patel NA, Villegas VM, Harbour JW, 2020 Jun Am J Ophthalmol Case Rep 18 100691
Seider MI, Berry DE, Schefler AC, Materin M, Stinnett S, Mruthyunjaya P,
2020 Feb
Graefes Arch Clin Exp Ophthalmol
2
258
427-435
A novel cardiomyogenic role for Isl1+ neural crest cells in the inflow tract.
Hatzistergos KE, Durante MA, Valasaki K, Wanschel ACBA, Harbour JW, Hare JM, 2020 Dec Sci Adv 49 6
Ashkenazy N, Orihuela G, Rodriguez LI, Negron CI, Harbour JW, Berrocal AM,
2020 11
Ophthalmic Surg Lasers Imaging Retina
11
51
651-652
Global Retinoblastoma Presentation and Analysis by National Income Level.
Fabian ID, Abdallah E, Abdullahi SU, Abdulqader RA, Adamou Boubacar S, Ademola-Popoola DS, Adio A, Afshar AR, Aggarwal P, Aghaji AE, Ahmad A, Akib MNR, Al Harby L, Al Ani MH, Alakbarova A, Portabella SA, Al-Badri SAF, Alcasabas APA, Al-Dahmash SA, Alejos A, Alemany-Rubio E, Alfa Bio AI, Alfonso Carreras Y, Al-Haddad C, Al-Hussaini HHY, Ali AM, Alia DB, Al-Jadiry MF, Al-Jumaily U, Alkatan HM, All-Eriksson C, Al-Mafrachi AARM, Almeida AA, Alsawidi KM, Al-Shaheen AASM, Al-Shammary EH, Amiruddin PO, Antonino R, Astbury NJ, Atalay HT, Atchaneeyasakul LO, Atsiaya R, Attaseth T, Aung TH, Ayala S, Baizakova B, Balaguer J, Balayeva R, Balwierz W, Barranco H, Bascaran C, Beck Popovic M, Benavides R, Benmiloud S, Bennani Guebessi N, Berete RC, Berry JL, Bhaduri A, Bhat S, Biddulph SJ, Biewald EM, Bobrova N, Boehme M, Boldt HC, Bonanomi MTBC, Bornfeld N, Bouda GC, Bouguila H, Boumedane A, Brennan RC, Brichard BG, Buaboonnam J, Calderón-Sotelo P, Calle Jara DA, Camuglia JE, Cano MR, Capra M, Cassoux N, Castela G, Castillo L, Català-Mora J, Chantada GL, Chaudhry S, Chaugule SS, Chauhan A, Chawla B, Chernodrinska VS, Chiwanga FS, Chuluunbat T, Cieslik K, Cockcroft RL, Comsa C, Correa ZM, Correa Llano MG, Corson TW, Cowan-Lyn KE, Csóka M, Cui X, Da Gama IV, Dangboon W, Das A, Das S, Davanzo JM, Davidson A, De Potter P, Delgado KQ, Demirci H, Desjardins L, Diaz Coronado RY, Dimaras H, Dodgshun AJ, Donaldson C, Donato Macedo CR, Dragomir MD, Du Y, Du Bruyn M, Edison KS, Eka Sutyawan IW, El Kettani A, Elbahi AM, Elder JE, Elgalaly D, Elhaddad AM, Elhassan MMA, Elzembely MM, Essuman VA, Evina TGA, Fadoo Z, Fandiño AC, Faranoush M, Fasina O, Fernández DDPG, Fernández-Teijeiro A, Foster A, Frenkel S, Fu LD, Fuentes-Alabi SL, Gallie BL, Gandiwa M, Garcia JL, García Aldana D, Gassant PY, Geel JA, Ghassemi F, Girón AV, Gizachew Z, Goenz MA, Gold AS, Goldberg-Lavid M, Gole GA, Gomel N, Gonzalez E, Gonzalez Perez G, González-Rodríguez L, Garcia Pacheco HN, Graells J, Green L, Gregersen PA, Grigorovski NDAK, Guedenon KM, Gunasekera DS, Gündüz AK, Gupta H, Gupta S, Hadjistilianou T, Hamel P, Hamid SA, Hamzah N, Hansen ED, Harbour JW, Hartnett ME, Hasanreisoglu M, Hassan S, Hassan S, Hederova S, Hernandez J, Hernandez LMC, Hessissen L, Hordofa DF, Huang LC, Hubbard GB, Hummlen M, Husakova K, Hussein Al-Janabi AN, Ida R, Ilic VR, Jairaj V, Jeeva I, Jenkinson H, Ji X, Jo DH, Johnson KP, Johnson WJ, Jones MM, Kabesha TBA, Kabore RL, Kaliki S, Kalinaki A, Kantar M, Kao LY, Kardava T, Kebudi R, Kepak T, Keren-Froim N, Khan ZJ, Khaqan HA, Khauv P, Kheir WJ, Khetan V, Khodabande A, Khotenashvili Z, Kim JW, Kim JH, Kiratli H, Kivelä TT, Klett A, Komba Palet JEK, Krivaitiene D, Kruger M, Kulvichit K, Kuntorini MW, Kyara A, Lachmann ES, Lam CPS, Lam GC, Larson SA, Latinovic S, Laurenti KD, Le BHA, Lecuona K, Leverant AA, Li C, Limbu B, Long QB, López JP, Lukamba RM, Lumbroso L, Luna-Fineman S, Lutfi D, Lysytsia L, Magrath GN, Mahajan A, Majeed AR, Maka E, Makan M, Makimbetov EK, Manda C, Martín Begue N, Mason L, Mason JO, Matende IO, Materin M, Mattosinho CCDS, Matua M, Mayet I, Mbumba FB, McKenzie JD, Medina-Sanson A, Mehrvar A, Mengesha AA, Menon V, Mercado GJVD, Mets MB, Midena E, Mishra DKC, Mndeme FG, Mohamedani AA, Mohammad MT, Moll AC, Montero MM, Morales RA, Moreira C, Mruthyunjaya P, Msina MS, Msukwa G, Mudaliar SS, Muma KI, Munier FL, Murgoi G, Murray TG, Musa KO, Mushtaq A, Mustak H, Muyen OM, Naidu G, Nair AG, Naumenko L, Ndoye Roth PA, Nency YM, Neroev V, Ngo H, Nieves RM, Nikitovic M, Nkanga ED, Nkumbe H, Nuruddin M, Nyaywa M, Obono-Obiang G, Oguego NC, Olechowski A, Oliver SCN, Osei-Bonsu P, Ossandon D, Paez-Escamilla MA, Pagarra H, Painter SL, Paintsil V, Paiva L, Pal BP, Palanivelu MS, Papyan R, Parrozzani R, Parulekar M, Pascual Morales CR, Paton KE, Pawinska-Wasikowska K, Pe'er J, Peña A, Peric S, Pham CTM, Philbert R, Plager DA, Pochop P, Polania RA, Polyakov VG, Pompe MT, Pons JJ, Prat D, Prom V, Purwanto I, Qadir AO, Qayyum S, Qian J, Rahman A, Rahman S, Rahmat J, Rajkarnikar P, Ramanjulu R, Ramasubramanian A, Ramirez-Ortiz MA, Raobela L, Rashid R, Reddy MA, Reich E, Renner LA, Reynders D, Ribadu D, Riheia MM, Ritter-Sovinz P, Rojanaporn D, Romero L, Roy SR, Saab RH, Saakyan S, Sabhan AH, Sagoo MS, Said AMA, Saiju R, Salas B, San Román Pacheco S, Sánchez GL, Sayalith P, Scanlan TA, Schefler AC, Schoeman J, Sedaghat A, Seregard S, Seth R, Shah AS, Shakoor SA, Sharma MK, Sherief ST, Shetye NG, Shields CL, Siddiqui SN, Sidi Cheikh S, Silva S, Singh AD, Singh N, Singh U, Singha P, Sitorus RS, Skalet AH, Soebagjo HD, Sorochynska T, Ssali G, Stacey AW, Staffieri SE, Stahl ED, Stathopoulos C, Stirn Kranjc B, Stones DK, Strahlendorf C, Suarez MEC, Sultana S, Sun X, Sundy M, Superstein R, Supriyadi E, Surukrattanaskul S, Suzuki S, Svojgr K, Sylla F, Tamamyan G, Tan D, Tandili A, Tarrillo Leiva FF, Tashvighi M, Tateshi B, Tehuteru ES, Teixeira LF, Teh KH, Theophile T, Toledano H, Trang DL, Traoré F, Trichaiyaporn S, Tuncer S, Tyau-Tyau H, Umar AB, Unal E, Uner OE, Urbak SF, Ushakova TL, Usmanov RH, Valeina S, van Hoefen Wijsard M, Varadisai A, Vasquez L, Vaughan LO, Veleva-Krasteva NV, Verma N, Victor AA, Viksnins M, Villacís Chafla EG, Vishnevskia-Dai V, Vora T, Wachtel AE, Wackernagel W, Waddell K, Wade PD, Wali AH, Wang YZ, Weiss A, Wilson MW, Wime ADC, Wiwatwongwana A, Wiwatwongwana D, Wolley Dod C, Wongwai P, Xiang D, Xiao Y, Yam JC, Yang H, Yanga JM, Yaqub MA, Yarovaya VA, Yarovoy AA, Ye H, Yousef YA, Yuliawati P, Zapata López AM, Zein E, Zhang C, Zhang Y, Zhao J, Zheng X, Zhilyaeva K, Zia N, Ziko OAO, Zondervan M, Bowman R, 2020 05 JAMA Oncol 5 6 685-695Decitabine limits escape from MEK inhibition in uveal melanoma.
Gonçalves J, Emmons MF, Faião-Flores F, Aplin AE, Harbour JW, Licht JD, Wink MR, Smalley KSM, 2020 05 Pigment Cell Melanoma Res 3 33 507-514Single-cell analysis of olfactory neurogenesis and differentiation in adult humans.
Durante MA, Kurtenbach S, Sargi ZB, Harbour JW, Choi R, Kurtenbach S, Goss GM, Matsunami H, Goldstein BJ, 2020 03 Nat Neurosci 3 23 323-326
Dean MK, Studenski MT, Paez-Escamilla MA, Walter SD, Kwon D, Markoe AM, Harbour JW, Samuels SE,
2019 May - Jun
Brachytherapy
3
18
404-410
Vitreoretinal lymphoma followed by systemic diffuse large B cell lymphoma.
Fan KC, Tran KD, Harbour JW, Dubovy SA, Patel NA, Albini TA, 2019 Jun J Ophthalmic Inflamm Infect 1 9 11
Durante MA, Walter SD, Paez-Escamilla M, Tokarev J, Decatur CL, Dubovy SR, Schefler AC, Harbour JW,
2019 12
JAMA Ophthalmol
12
137
1434-1439
HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma.
Faião-Flores F, Emmons MF, Durante MA, Kinose F, Saha B, Fang B, Koomen JM, Chellappan SP, Maria-Engler SS, Rix U, Licht JD, Harbour JW, Smalley KSM, 2019 09 Clin Cancer Res 18 25 5686-5701
Paez-Escamilla M, Walter SD, Mohsenin A, Decatur CL, Harocopos GJ, Dubovy S, Harbour JW,
2019 09
Ophthalmic Surg Lasers Imaging Retina
9
50
573-579
Anbunathan H, Verstraten R, Singh AD, Harbour JW, Bowcock AM,
2019 08
Clin Cancer Res
16
25
5156-5166
Husnain M, Mackrides N, Vega F, Paez-Escamilla M, Markoe AM, Harbour JW, Lossos IS,
2019 05
Leuk Lymphoma
5
60
1308-1311
An Eight-Year-Old Girl Presents With Two Weeks of Vision Loss and Nightly Headaches.
Scott NL, Tran KD, Cernichiaro-Espinosa LA, Russell JF, Hinkle JW, Harbour JW, Dubovy SR, Berrocal AM, 2019 05 Ophthalmic Surg Lasers Imaging Retina 5 50 314-317
de la Fuente MI, Alderuccio JP, Reis IM, Omuro A, Markoe A, Echegaray JJ, Davis JL, Harbour JW, Lossos IS,
2019 04
Am J Hematol
4
94
455-460
Jeng-Miller KW, Soomro T, Scott NL, Rao P, Marlow E, Chang EY, Ells A, Chau F, Nudleman E, Calvo CM, Patel N, Schwartz R, Cernichiaro-Espinosa LA, Montoya AG, Goldstein J, Harper CA, Baumal CR, Hartnett ME, Harbour JW, Besirli CG, Gupta MP, Chan RVP, Drenser KA, Capone A, Murray TG, Mukai S, Trese MT, Berrocal AM, Wong SC, Yonekawa Y,
2019 04
Ophthalmic Surg Lasers Imaging Retina
4
50
221-227
Persistent fetal vasculature presenting with axial elongation and platyphakia.
Lin J, Paez-Escamilla M, Teira LE, Fallas B, Harbour JW, 2019 02 J AAPOS 1 23 51-53
Kurtenbach S, Reddy R, Harbour JW,
2019 01
Nucleic Acids Res
D1
47
D46-D49
Harbour JW, Paez-Escamilla M, Cai L, Walter SD, Augsburger JJ, Correa ZM,
2019 01
Am J Ophthalmol
197
168-179
Follow the nevus: the cost-utility of monitoring for growth of choroidal nevi.
Barsam AS, Gibbons A, McClellan AJ, Harbour JW, Smiddy WE, 2019 Int J Ophthalmol 9 12 1456-1464
Paez-Escamilla M, Bagheri N, Harbour JW,
2018 Jan
JAMA Ophthalmol
1
136
e175064
Drug and disease signature integration identifies synergistic combinations in glioblastoma.
Stathias V, Jermakowicz AM, Maloof ME, Forlin M, Walters W, Suter RK, Durante MA, Williams SL, Harbour JW, Volmar CH, Lyons NJ, Wahlestedt C, Graham RM, Ivan ME, Komotar RJ, Sarkaria JN, Subramanian A, Golub TR, Schürer SC, Ayad NG, 2018 12 Nat Commun 1 9 5315Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide.
Walpole S, Pritchard AL, Cebulla CM, Pilarski R, Stautberg M, Davidorf FH, de la Fouchardière A, Cabaret O, Golmard L, Stoppa-Lyonnet D, Garfield E, Njauw CN, Cheung M, Turunen JA, Repo P, Järvinen RS, van Doorn R, Jager MJ, Luyten GPM, Marinkovic M, Chau C, Potrony M, Höiom V, Helgadottir H, Pastorino L, Bruno W, Andreotti V, Dalmasso B, Ciccarese G, Queirolo P, Mastracci L, Wadt K, Kiilgaard JF, Speicher MR, van Poppelen N, Kilic E, Al-Jamal RT, Dianzani I, Betti M, Bergmann C, Santagata S, Dahiya S, Taibjee S, Burke J, Poplawski N, O'Shea SJ, Newton-Bishop J, Adlard J, Adams DJ, Lane AM, Kim I, Klebe S, Racher H, Harbour JW, Nickerson ML, Murali R, Palmer JM, Howlie M, Symmons J, Hamilton H, Warrier S, Glasson W, Johansson P, Robles-Espinoza CD, Ossio R, de Klein A, Puig S, Ghiorzo P, Nielsen M, Kivelä TT, Tsao H, Testa JR, Gerami P, Stern MH, Paillerets BB, Abdel-Rahman MH, Hayward NK, 2018 12 J Natl Cancer Inst 12 110 1328-1341
Cai L, Paez-Escamilla M, Walter SD, Tarlan B, Decatur CL, Perez BM, Harbour JW,
2018 11
Am J Ophthalmol
195
154-160
Paez-Escamilla M, Walter SD, Ramaiya KJ, Harbour JW,
2018 10
Ophthalmic Surg Lasers Imaging Retina
10
49
812-814
Reduced BAP1 activity prevents ASXL1 truncation-driven myeloid malignancy in vivo.
Guo Y, Yang H, Chen S, Zhang P, Li R, Nimer SD, Harbour JW, Xu M, Yang FC, 2018 08 Leukemia 8 32 1834-1837
Harbour JW, Paez-Escamilla M,
2018 05
JAMA Ophthalmol
5
136
597
Garoon RB, Harbour JW,
2018 04
Ophthalmic Surg Lasers Imaging Retina
4
49
276-277
Peng H, Prokop J, Karar J, Park K, Cao L, Harbour JW, Bowcock AM, Malkowicz SB, Cheung M, Testa JR, Rauscher FJ,
2018 03
Cancer Res
5
78
1200-1213
Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies.
Yang H, Kurtenbach S, Guo Y, Lohse I, Durante MA, Li J, Li Z, Al-Ali H, Li L, Chen Z, Field MG, Zhang P, Chen S, Yamamoto S, Li Z, Zhou Y, Nimer SD, Harbour JW, Wahlestedt C, Xu M, Yang FC, 2018 01 Blood 3 131 328-341
Mruthyunjaya P, Seider MI, Stinnett S, Schefler A
2017 May
Ophthalmology
Li Z, Zhang P, Yan A, Guo Z, Ban Y, Li J, Chen S, Yang H, He Y, Li J, Guo Y, Zhang W, Hajiramezanali E, An H, Fajardo D, Harbour JW, Ruan Y, Nimer SD, Yu P, Chen X, Xu M, Yang FC,
2017 Jan
Sci Adv
1
3
e1601602
Harbour JW,
2017 Feb
JAMA Ophthalmol
2
135
175-176
Intracameral Topotecan Hydrochloride for Anterior Chamber Seeding of Retinoblastoma.
Paez-Escamilla M, Bagheri N, Teira LE, Corrales-Medina FF, Harbour W, 2017 Dec JAMA Ophthalmol 12 135 1453-1454
Fernandez MP, Al-Holou SN, Fischer O, Murray T, Harbour JW, Dubovy SR, Berrocal AM,
2017 Aug
J AAPOS
4
21
337-339.e2
Molecular Characteristics of Conjunctival Melanoma Using Whole-Exome Sequencing.
Swaminathan SS, Field MG, Sant D, Wang G, Galor A, Dubovy SR, Harbour JW, Karp CL, 2017 12 JAMA Ophthalmol 12 135 1434-1437
Harbour JW,
2017 11
JAMA Ophthalmol
11
135
1231
Harbour JW, Paez-Escamilla M,
2017 10
Invest Ophthalmol Vis Sci
12
58
5444
Multimodal Imaging of Astrocytic Hamartomas Associated With Tuberous Sclerosis.
Schwartz SG, Harbour JW, 2017 09 Ophthalmic Surg Lasers Imaging Retina 9 48 756-758
Harbour JW,
2017 07
JAMA Ophthalmol
7
135
819-820
PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
Gezgin G, Luk SJ, Cao J, Dogrusöz M, van der Steen DM, Hagedoorn RS, Krijgsman D, van der Velden PA, Field MG, Luyten GPM, Szuhai K, Harbour JW, Jordanova ES, Heemskerk MHM, Jager MJ, 2017 06 JAMA Ophthalmol 6 135 541-549
Mohney BG, Elner VM, Smith AB, Harbour JW, Smith BD, Musch DC, Smith SJ,
2017 02
Ophthalmic Surg Lasers Imaging Retina
2
48
151-159
An international survey of classification and treatment choices for group D retinoblastoma.
Scelfo C, Francis JH, Khetan V, Jenkins T, Marr B, Abramson DH, Shields CL, Pe'er J, Munier F, Berry J, Harbour JW, Yarovoy A, Lucena E, Murray TG, Bhagia P, Paysse E, Tuncer S, Chantada GL, Moll AC, Ushakova T, Plager DA, Ziyovuddin I, Leal CA, Materin MA, Ji XD, Cursino JW, Polania R, Kiratli H, All-Ericsson C, Kebudi R, Honavar SG, Vishnevskia-Dai V, Epelman S, Daniels AB, Ling JD, Traore F, Ramirez-Ortiz MA, 2017 Int J Ophthalmol 6 10 961-967
Field MG, Durante MA, Decatur CL, Tarlan B, Oelschlager KM, Stone JF, Kuznetsov J, Bowcock AM, Kurtenbach S, Harbour JW,
2016 Sep
Oncotarget
37
7
59209-59219
Walter SD, Chao DL, Feuer W, Schiffman J, Char DH, Harbour JW,
2016 Jul
JAMA Ophthalmol
7
134
734-40
Uveal and Conjunctival Melanoma: Close Together-but Only Distantly Related.
Harbour JW, 2016 Jan Oncology (Williston Park) 1 30 44, 48
Fedorenko IV, Evernden B, Kenchappa RS, Sahebjam S, Ryzhova E, Puskas J, McIntosh L, Caceres G, Magliocco A, Etame A, Harbour JW, Smalley KS, Forsyth PA,
2016 10
Melanoma Res
5
26
481-6
Rao RC, Harbour JW,
2016 09
JAMA Ophthalmol
9
134
1063-4
Driver Mutations in Uveal Melanoma: Associations With Gene Expression Profile and Patient Outcomes.
Decatur CL, Ong E, Garg N, Anbunathan H, Bowcock AM, Field MG, Harbour JW, 2016 07 JAMA Ophthalmol 7 134 728-33
Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, Atkins MB, Bosenberg MW, Dummer R, Gershenwald JE, Halpern AC, Herlyn D, Karakousis GC, Kirkwood JM, Krauthammer M, Lo RS, Long GV, McArthur G, Ribas A, Schuchter L, Sosman JA, Smalley KS, Steeg P, Thomas NE, Tsao H, Tueting T, Weeraratna A, Xu G, Lomax R, Martin A, Silverstein S, Turnham T, Ronai ZA,
2016 07
Pigment Cell Melanoma Res
4
29
404-16
ARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal Melanoma.
Yoo JH, Shi DS, Grossmann AH, Sorensen LK, Tong Z, Mleynek TM, Rogers A, Zhu W, Richards JR, Winter JM, Zhu J, Dunn C, Bajji A, Shenderovich M, Mueller AL, Woodman SE, Harbour JW, Thomas KR, Odelberg SJ, Ostanin K, Li DY, 2016 06 Cancer Cell 6 29 889-904
Schwartz SG, Harbour JW,
2015 May
Ophthalmic Surg Lasers Imaging Retina
5
46
586-8
Gene expression profiling and regression rate of irradiated uveal melanomas.
Rao RC, Khan M, Badiyan SN, Harbour JW, 2015 Mar Ophthalmic Surg Lasers Imaging Retina 3 46 333-7Skewed expression of the genes encoding epigenetic modifiers in high-risk uveal melanoma.
Herlihy N, Dogrusöz M, van Essen TH, Harbour JW, van der Velden PA, van Eggermond MC, Haasnoot GW, van den Elsen PJ, Jager MJ, 2015 Jan Invest Ophthalmol Vis Sci 3 56 1447-58
Chao DL, Harbour JW,
2015 Apr
Can J Ophthalmol
2
50
151-4
Serous macular detachment following a systemic corticosteroid injection.
Weng CY, Harbour JW, 2015 Apr JAMA Ophthalmol 4 133 473-4Epigenetic reprogramming of melanoma cells by vitamin C treatment.
Gustafson CB, Yang C, Dickson KM, Shao H, Van Booven D, Harbour JW, Liu ZJ, Wang G, 2015 Clin Epigenetics 7 51EMT-associated factors promote invasive properties of uveal melanoma cells.
Asnaghi L, Gezgin G, Tripathy A, Handa JT, Merbs SL, van der Velden PA, Jager MJ, Harbour JW, Eberhart CG, 2015 Mol Vis 21 919-29Combined PKC and MEK inhibition for treating metastatic uveal melanoma.
Sagoo MS, Harbour JW, Stebbing J, Bowcock AM, 2014 Sep Oncogene 39 33 4722-3Distinguishing torpedo maculopathy from similar lesions of the posterior segment.
Villegas VM, Schwartz SG, Flynn HW, Capó H, Berrocal AM, Murray TG, Harbour JW, 2014 May-Jun Ophthalmic Surg Lasers Imaging Retina 3 45 222-6Recent developments in prognostic and predictive testing in uveal melanoma.
Field MG, Harbour JW, 2014 May Curr Opin Ophthalmol 3 25 234-9
Badiyan SN, Rao RC, Apicelli AJ, Acharya S, Verma V, Garsa AA, DeWees T, Speirs CK, Garcia-Ramirez J, Esthappan J, Grigsby PW, Harbour JW,
2014 Mar
Int J Radiat Oncol Biol Phys
4
88
801-5
GNAQ/11 mutations in uveal melanoma: is YAP the key to targeted therapy?
Field MG, Harbour JW, 2014 Jun Cancer Cell 6 25 714-5A molecular revolution in uveal melanoma: implications for patient care and targeted therapy.
Harbour JW, Chao DL, 2014 Jun Ophthalmology 6 121 1281-8Prognostic parameters in uveal melanoma and their association with BAP1 expression.
van Essen TH, van Pelt SI, Versluis M, Bronkhorst IH, van Duinen SG, Marinkovic M, Kroes WG, Ruivenkamp CA, Shukla S, de Klein A, Kiliç E, Harbour JW, Luyten GP, van der Velden PA, Verdijk RM, Jager MJ, 2014 Dec Br J Ophthalmol 12 98 1738-43
Chen RW, Harbour JW,
2014 Dec
Graefes Arch Clin Exp Ophthalmol
12
252
2021-2
Harbour JW,
2014
Methods Mol Biol
1102
427-40
Molecular testing prognostic of low risk in epithelioid uveal melanoma in a child.
Dimaras H, Parulekar MV, Kwok G, Simpson ER, Ali A, Halliday W, Shago M, Harbour JW, Héon E, Gallie BL, Chan HS, 2013 Mar Br J Ophthalmol 3 97 323-6Patient-derived xenografts recapitulate molecular features of human uveal melanomas.
Laurent C, Gentien D, Piperno-Neumann S, Némati F, Nicolas A, Tesson B, Desjardins L, Mariani P, Rapinat A, Sastre-Garau X, Couturier J, Hupé P, de Koning L, Dubois T, Roman-Roman S, Stern MH, Barillot E, Harbour JW, Saule S, Decaudin D, 2013 Jun Mol Oncol 3 7 625-36
Harbour JW, Augsburger JJ, Char DH,
2013 Jul
Ophthalmology
7
120
e52-3
Harbour JW, Augsburger JJ, Char DH,
2013 Jul
Ophthalmology
7
120
e51
Harbour JW, Wilson D, Finger PT, Worley LA, Onken MD,
2013 Jan
Ophthalmology
1
120
213, 213.e1-3
A role for Jag2 in promoting uveal melanoma dissemination and growth.
Asnaghi L, Handa JT, Merbs SL, Harbour JW, Eberhart CG, 2013 Jan Invest Ophthalmol Vis Sci 1 54 295-306Retinoblastoma protein prevents enteric nervous system defects and intestinal pseudo-obstruction.
Fu M, Landreville S, Agapova OA, Wiley LA, Shoykhet M, Harbour JW, Heuckeroth RO, 2013 Dec J Clin Invest 12 123 5152-64
Modi YS, Epstein A, Bhaleeya S, Harbour JW, Albini T,
2013 Aug
J Ophthalmic Inflamm Infect
1
3
58
BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma.
Matatall KA, Agapova OA, Onken MD, Worley LA, Bowcock AM, Harbour JW, 2013 Aug BMC Cancer 13 371
Harbour JW, Chen R,
2013 Apr
PLoS Curr
5
Impaired cholesterol efflux in senescent macrophages promotes age-related macular degeneration.
Sene A, Khan AA, Cox D, Nakamura RE, Santeford A, Kim BM, Sidhu R, Onken MD, Harbour JW, Hagbi-Levi S, Chowers I, Edwards PA, Baldan A, Parks JS, Ory DS, Apte RS, 2013 Apr Cell Metab 4 17 549-61Genomic, prognostic, and cell-signaling advances in uveal melanoma.
Harbour JW, 2013 Am Soc Clin Oncol Educ Book 388-91High throughput mass spectrometry-based mutation profiling of primary uveal melanoma.
Daniels AB, Lee JE, MacConaill LE, Palescandolo E, Van Hummelen P, Adams SM, DeAngelis MM, Hahn WC, Gragoudas ES, Harbour JW, Garraway LA, Kim IK, 2012 Oct Invest Ophthalmol Vis Sci 11 53 6991-6The genetics of uveal melanoma: an emerging framework for targeted therapy.
Harbour JW, 2012 Mar Pigment Cell Melanoma Res 2 25 171-81
Harbour JW,
2012 Jul
Clin Adv Hematol Oncol
7
10
459-61
Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.
Landreville S, Agapova OA, Matatall KA, Kneass ZT, Onken MD, Lee RS, Bowcock AM, Harbour JW, 2012 Jan Clin Cancer Res 2 18 408-16Notch signaling promotes growth and invasion in uveal melanoma.
Asnaghi L, Ebrahimi KB, Schreck KC, Bar EE, Coonfield ML, Bell WR, Handa J, Merbs SL, Harbour JW, Eberhart CG, 2012 Feb Clin Cancer Res 3 18 654-65Uveal melanoma: molecular pattern, clinical features, and radiation response.
Chappell MC, Char DH, Cole TB, Harbour JW, Mishra K, Weinberg VK, Phillips TL, 2012 Aug Am J Ophthalmol 2 154 227-232.e2Diagnostic testing and treatment choices in primary vitreoretinal lymphoma.
Rajagopal R, Harbour JW, 2011 Mar Retina 3 31 435-40ABCB1 identifies a subpopulation of uveal melanoma cells with high metastatic propensity.
Landreville S, Agapova OA, Kneass ZT, Salesse C, Harbour JW, 2011 Jun Pigment Cell Melanoma Res 3 24 430-7
Delston RB, Matatall KA, Sun Y, Onken MD, Harbour JW,
2011 Feb
Oncogene
5
30
588-99
Harbour JW,
2011 Dec
Pigment Cell Melanoma Res
6
24
1081-2
Chan CC, Rubenstein JL, Coupland SE, Davis JL, Harbour JW, Johnston PB, Cassoux N, Touitou V, Smith JR, Batchelor TT, Pulido JS,
2011
Oncologist
11
16
1589-99
Association between gene expression profile, proliferation and metastasis in uveal melanoma.
Onken MD, Worley LA, Harbour JW, 2010 Sep Curr Eye Res 9 35 857-63
Landreville S, Ma D, Wu J, Harbour JW,
2010 May
Curr Eye Res
5
35
435-9
A transformation in ocular oncology: from megacenter to multicenter.
Harbour JW, 2010 Mar Arch Ophthalmol 3 128 367-8
Woo KI, Harbour JW,
2010 Jul
Arch Ophthalmol
7
128
865-70
Onken MD, Worley LA, Tuscan MD, Harbour JW,
2010 Jul
J Mol Diagn
4
12
461-8
Id2 deficiency promotes metastasis in a mouse model of ocular cancer.
Agapova OA, Person E, Harbour JW, 2010 Feb Clin Exp Metastasis 2 27 91-6
Dayani PN, Gould JE, Brown DB, Sharma KV, Linette GP, Harbour JW,
2009 May
Arch Ophthalmol
5
127
628-32
Molecular prognostic testing and individualized patient care in uveal melanoma.
Harbour JW, 2009 Dec Am J Ophthalmol 6 148 823-9.e1
Finger PT,
2009 Aug
Arch Pathol Lab Med
8
133
1197-8
Emerging insights into the molecular pathogenesis of uveal melanoma.
Landreville S, Agapova OA, Harbour JW, 2008 Oct Future Oncol 5 4 629-36Correlation study of benign cytomorphology and final clinical diagnosis.
Zhai J, Harbour JW, Smith ME, Dávila RM, 2008 Mar-Apr Acta Cytol 2 52 196-200
Onken MD, Worley LA, Harbour JW,
2008 Jun
Clin Cancer Res
12
14
3737-45
Chang SH, Worley LA, Onken MD, Harbour JW,
2008 Jun
Melanoma Res
3
18
191-200
Worley LA, Long MD, Onken MD, Harbour JW,
2008 Jun
Melanoma Res
3
18
184-90
Hepatic arterial chemoembolization for management of metastatic melanoma.
Sharma KV, Gould JE, Harbour JW, Linette GP, Pilgram TK, Dayani PN, Brown DB, 2008 Jan AJR Am J Roentgenol 1 190 99-104Tilting of radioactive plaques after initial accurate placement for treatment of uveal melanoma.
Almony A, Breit S, Zhao H, Garcia-Ramirez J, Mansur DB, Harbour JW, 2008 Jan Arch Ophthalmol 1 126 65-70Integrative genomic analysis of aneuploidy in uveal melanoma.
Ehlers JP, Worley L, Onken MD, Harbour JW, 2008 Jan Clin Cancer Res 1 14 115-22
Onken MD, Worley LA, Long MD, Duan S, Council ML, Bowcock AM, Harbour JW,
2008 Dec
Invest Ophthalmol Vis Sci
12
49
5230-4
Harbour JW,
2008 Aug
Cell Cycle
15
7
2276-7
Treatment outcomes for primary intraocular lymphoma: implications for external beam radiotherapy.
Berenbom A, Davila RM, Lin HS, Harbour JW, 2007 Sep Eye (Lond) 9 21 1198-201
Onken MD, Worley LA, Person E, Char DH, Bowcock AM, Harbour JW,
2007 May
Clin Cancer Res
10
13
2923-7
Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma.
Worley LA, Onken MD, Person E, Robirds D, Branson J, Char DH, Perry A, Harbour JW, 2007 Mar Clin Cancer Res 5 13 1466-71Molecular prognostic testing in uveal melanoma: has it finally come of age?
Harbour JW, 2007 Aug Arch Ophthalmol 8 125 1122-3
Apte RS, Harbour JW,
2007
Ophthalmic Res
4
39
188-90
Rb at the interface between cell cycle and apoptotic decisions.
Delston RB, Harbour JW, 2006 Nov Curr Mol Med 7 6 713-8Prognostic testing in uveal melanoma by transcriptomic profiling of fine needle biopsy specimens.
Onken MD, Worley LA, Dávila RM, Char DH, Harbour JW, 2006 Nov J Mol Diagn 5 8 567-73Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas.
Onken MD, Ehlers JP, Worley LA, Makita J, Yokota Y, Harbour JW, 2006 May Cancer Res 9 66 4602-9Eye cancer: unique insights into oncogenesis: the Cogan Lecture.
Harbour JW, 2006 May Invest Ophthalmol Vis Sci 5 47 1736-45Lipid exudation following plaque radiotherapy for posterior uveal melanoma.
Mills MD, Harbour JW, 2006 Mar Am J Ophthalmol 3 141 594-595
Ehlers JP, Harbour JW,
2006
Int Ophthalmol Clin
1
46
167-80
Onken MD, Lin AY, Worley LA, Folberg R, Harbour JW,
2005 Oct
Am J Ophthalmol
4
140
748-9
Fine needle aspiration biopsy with adjunct immunohistochemistry in intraocular tumor management.
Faulkner-Jones BE, Foster WJ, Harbour JW, Smith ME, Dávila RM, 2005 May-Jun Acta Cytol 3 49 297-308Functional analysis of the p53 pathway in response to ionizing radiation in uveal melanoma.
Sun Y, Tran BN, Worley LA, Delston RB, Harbour JW, 2005 May Invest Ophthalmol Vis Sci 5 46 1561-4DDEF1 is located in an amplified region of chromosome 8q and is overexpressed in uveal melanoma.
Ehlers JP, Worley L, Onken MD, Harbour JW, 2005 May Clin Cancer Res 10 11 3609-13
Lieman JH, Worley LA, Harbour JW,
2005 Mar
J Biol Chem
11
280
10484-90
Ehlers JP, Harbour JW,
2005 Mar
Clin Cancer Res
5
11
1849-53
Singh AD, Damato B, Howard P, Harbour JW,
2005 Mar
Ophthalmol Clin North Am
1
18
85-97, viii
Loercher AE, Tank EM, Delston RB, Harbour JW,
2005 Jan
J Cell Biol
1
168
35-40
Harbour JW,
2004 Sep
Am J Ophthalmol
3
138
471-3
Onken MD, Worley LA, Ehlers JP, Harbour JW,
2004 Oct
Cancer Res
20
64
7205-9
For whom the bell tolls: susceptibility to common adult cancers in retinoblastoma survivors.
Kaye FJ, Harbour JW, 2004 Mar J Natl Cancer Inst 5 96 342-3Photodynamic therapy for choroidal metastasis from carcinoid tumor.
Harbour JW, 2004 Jun Am J Ophthalmol 6 137 1143-5Cytologic diagnosis of intraocular lymphoma in vitreous aspirates.
Farkas T, Harbour JW, Dávila RM, 2004 Jul-Aug Acta Cytol 4 48 487-91
Espinoza G, Rosenblatt B, Harbour JW,
2004 Jan
Am J Ophthalmol
1
137
90-5
Association between choroidal pigmentation and posterior uveal melanoma in a white population.
Harbour JW, Brantley MA, Hollingsworth H, Gordon M, 2004 Jan Br J Ophthalmol 1 88 39-43Association between posterior uveal melanoma and iris freckles, iris naevi, and choroidal naevi.
Harbour JW, Brantley MA, Hollingsworth H, Gordon M, 2004 Jan Br J Ophthalmol 1 88 36-8Pars plana vitrectomy in eyes containing a treated posterior uveal melanoma.
Foster WJ, Harbour JW, Holekamp NM, Shah GK, Thomas MA, 2003 Sep Am J Ophthalmol 3 136 471-6
Foster WJ, Fuller CE, Perry A, Harbour JW,
2003 Sep
Arch Ophthalmol
9
121
1311-5
Transpupillary thermotherapy versus plaque radiotherapy for suspected choroidal melanomas.
Harbour JW, Meredith TA, Thompson PA, Gordon ME, 2003 Nov Ophthalmology 11 110 2207-14; discussion 2215Distinct mechanisms for regulating the tumor suppressor and antiapoptotic functions of Rb.
Ma D, Zhou P, Harbour JW, 2003 May J Biol Chem 21 278 19358-66Ocular melanoma: a review and the relationship to cutaneous melanoma.
Hurst EA, Harbour JW, Cornelius LA, 2003 Aug Arch Dermatol 8 139 1067-73
Loercher AE, Harbour JW,
2003 Aug
Curr Eye Res
2
27
69-74
Transducible peptide therapy for uveal melanoma and retinoblastoma.
Harbour JW, Worley L, Ma D, Cohen M, 2002 Oct Arch Ophthalmol 10 120 1341-6Rate of resolution of exudative retinal detachment after plaque radiotherapy for uveal melanoma.
Harbour JW, Ahmad S, El-Bash M, 2002 Nov Arch Ophthalmol 11 120 1463-9
Finger PT, Harbour JW, Karcioglu ZA,
2002 Jan-Feb
Surv Ophthalmol
1
47
1-16
Altered expression of Rb and p53 in uveal melanomas following plaque radiotherapy.
Brantley MA, Worley L, Harbour JW, 2002 Feb Am J Ophthalmol 2 133 242-8Photodynamic therapy for circumscribed choroidal hemangioma.
Sheidow TG, Harbour JW, 2002 Aug Can J Ophthalmol 5 37 314-7
Harbour JW,
2001 Nov
Arch Ophthalmol
11
119
1699-704
Brantley MA, Harbour JW,
2001 Mar
Ocul Immunol Inflamm
1
9
1-8
Harbour JW, Dean DC,
2001
Curr Top Microbiol Immunol
254
137-44
Harbour JW, Dean DC,
2000 Oct
Genes Dev
19
14
2393-409
Zhang HS, Gavin M, Dahiya A, Postigo AA, Ma D, Luo RX, Harbour JW, Dean DC,
2000 Mar
Cell
1
101
79-89
Brantley MA, Harbour JW,
2000 Dec
Am J Pathol
6
157
1795-801
Harbour JW, Dean DC,
2000 Dec
Curr Opin Cell Biol
6
12
685-9
Brantley MA, Harbour JW,
2000 Aug
Cancer Res
16
60
4320-3
Harbour JW, Dean DC,
2000 Apr
Nat Cell Biol
4
2
E65-7
Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC,
1999 Sep
Cell
6
98
859-69
Harbour JW,
1999 Nov-Dec
Surv Ophthalmol
3
44
235-46
Harbour JW,
1998 Aug
Ophthalmology
8
105
1442-7
Langerhans cell histiocytosis diagnosed by fine needle biopsy.
Harbour JW, Char DH, Ljung BM, Luna-Fineman S, 1997 Sep Arch Ophthalmol 9 115 1212-3
Harbour JW, Char DH, Kroll S, Quivey JM, Castro J,
1997 Nov
Ophthalmology
11
104
1785-92; discussion 1792-3
Pars plana vitrectomy in the management of phakic and pseudophakic malignant glaucoma.
Harbour JW, Rubsamen PE, Palmberg P, 1996 Sep Arch Ophthalmol 9 114 1073-8Local carboplatin therapy in transgenic murine retinoblastoma.
Harbour JW, Murray TG, Hamasaki D, Cicciarelli N, Hernández E, Smith B, Windle J, O'Brien JM, 1996 Aug Invest Ophthalmol Vis Sci 9 37 1892-8
Harbour JW, Smiddy WE, Flynn HW, Rubsamen PE,
1996 Apr
Am J Ophthalmol
4
121
405-13
Harbour JW, Murray TG, Byrne SF, Hughes JR, Gendron EK, Ehlies FJ, Markoe AM,
1996
Retina
2
16
129-34
Pars plana vitrectomy for chronic pseudophakic cystoid macular edema.
Harbour JW, Smiddy WE, Rubsamen PE, Murray TG, Davis JL, Flynn HW, 1995 Sep Am J Ophthalmol 3 120 302-7Initial management and follow-up of melanocytic iris tumors.
Harbour JW, Augsburger JJ, Eagle RC, 1995 Dec Ophthalmology 12 102 1987-93Uveal metastasis from carcinoid tumor. Clinical observations in nine cases.
Harbour JW, De Potter P, Shields CL, Shields JA, 1994 Jun Ophthalmology 6 101 1084-90Clivus chordoma: a report of 12 recent cases and review of the literature.
Harbour JW, Lawton MT, Criscuolo GR, Holliday MJ, Mattox DE, Long DM, 1991 Skull Base Surg 4 1 200-6Expression in lung cancer of a transcribed sequence at the DNF15S2 locus at chromosome 3P21.
Harbour JW, Lai SL, Gazdar AF, Minna JD, Kaye FJ, 1990 Jan-Feb Anticancer Res 1 10 23-7Loss of heterozygosity in a gene coding for a thyroid hormone receptor in lung cancers.
Leduc F, Brauch H, Hajj C, Dobrovic A, Kaye F, Gazdar A, Harbour JW, Pettengill OS, Sorenson GD, van den Berg A, 1989 Feb Am J Hum Genet 2 44 282-7Abnormalities in structure and expression of the human retinoblastoma gene in SCLC.
Harbour JW, Lai SL, Whang-Peng J, Gazdar AF, Minna JD, Kaye FJ, 1988 Jul Science 4863 241 353-7